Completed PHASE2 INTERVENTIONAL 2-arm NCT01313143

A Short Term Pharmacokinetic, Pharmacodynamic and Tolerability Study to Compare AOP200704 vs. Esmolol

A Prospective, Randomized, Double Blinded, Crossover, Two-treatment, Two-sequence, Short Term Pharmacokinetic, Pharmacodynamic and Tolerability, Single Centre Study to Compare AOP200704 vs. Esmolol in Healthy Subjects.

Sponsor: AOP Orphan Pharmaceuticals AG

Conditions Healthy Volunteers Pharmacokinetics/Dynamics Study

Interventions AOP200704 Esmolol hydrochloride, infusion

Updated 6 times since 2017 Last updated: Jul 18, 2012 Started: Mar 31, 2011 Primary completion: May 31, 2011 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Healthy Volunteers and Pharmacokinetics/Dynamics Study, this trial is completed. The trial is conducted by AOP Orphan Pharmaceuticals AG and has accumulated 6 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AOP Orphan Pharmaceuticals AG

Data source: AOP Orphan Pharmaceuticals AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pilsen, Czechia